The Serum Institute of India has halted the production of the Covishield (AstraZeneca) vaccine amid a glut of vaccine supplies. The SII's stockpile of vaccines has swelled to 200 million doses. The export of Covid vaccines had been earlier restricted, but resumed in November last year. The SII had recently appealed to the government to cut the gap between the second dose and the "precautionary" dose to just six months.
Courtesy: The Times of India
The Kerala HC has sought the Centre's response over a plea regarding a post-Covid-19 vaccination death. The post-mortem report of the deceased confirmed that death was due to intracranial bleeding. The Medical officer suspects that it was a case of thrombosis-with-thrombocytopenia-syndrome (TTS), a rare but well-known adverse event associated with the adenovirus vector-based Covishield vaccine. The plea argues that the victim had not been… read-more
Courtesy: Live Law
The PGI Chandigarh has got the approval of the drug regulator of India to study the mixing of Covid-19 vaccines. The study would help conclude what happens when a person who is fully vaccinated with either Covishield or Covaxin would respond to getting the booster dose of the other vaccine. The purpose of the study is also to compare homologous vaccination to heterologous vaccination.
Courtesy: The Economic Times
Pune based Serum Institute of India (SII) on February 4, wrote to Union Health Minister Mansukh Mandaviya, to reduce booster dose gap from nine months to three. The SII Director and Government Affairs official Prakash Kumar Singh, further asked to allow Covishield precaution dose for all above 18-years-old. The letter was written on the lines of revised guidelines, allowing booster dose for people on election duties with three months gap. … read-more
Courtesy: One India
The two COVID-19 vaccines, Covishield and Covaxin will soon get the regular market approval with capped prices. According to the Drug Controller General of India, the SII and Bharat Biotech urged the DGCI to grant regular market approval for adult population with certain conditions. If approved, vaccines will be available at Rs 275 plus Rs 150 additional charges. Notably, Covaxin and Covishield are available at Rs 1,200 and 780, respectively… read-more
Courtesy: Zee News
Adar Poonwalla, CEO of the Serum Institute of India (SII) applied for full market authorisation of its COVID-19 vaccine, Covishield, on December 31. "Supplies of Covishield vaccine in India, exceeded 1.25 billion doses. The Government of India now has enough data to allow full market authorisation," tweeted SII CEO. The application has been submitted to the Union Government and MoHFW. Besides, SII's Covishield also export vaccine doses to… read-more
Courtesy: News 18
As per reports, India's drug regulator has allowed Covishield's maker Serum Institute of India (SII) to enroll children aged between seven to 11 years for its COVID-19 vaccine trial. The Central Drugs Standard Control Organisation's (CDSCO) subject expert panel made the recommendation after "detailed deliberation". SII is already conducting a trial of its COVID-19 vaccine in the 12-17 age group and has presented safety data for an initial 100… read-more
According to research, the COVID antibodies response is better when there is an interval of 44-45 weeks between the first and second doses of Oxford-Covishield-Vaccine. “The encouraging results support a strategy of delayed second dosing because antibody titres (concentration) were substantially higher after the second dose among individuals with almost a year between doses than among individuals who had an 8–12 week interval," says the… read-more
Courtesy: The Print
The government is soon planning to reduce the interval between the two jabs of the Covishield vaccine for those who are 45 years and 45 due to the good availability of the vaccine "In two to four weeks, dosage interval of Covishield will be reduced based on final scientific evidence," said the National Technical Advisory Group on Immunisation in India (NTAGI). The current interval is 12-16 weeks.
After India's formal request & threaten with mandatory quarantine, the seven EU nations have now agreed on June 1 to include Covishield & Covaxin in the Green Pass list. Switzerland, Iceland, and other EU nations - Austria, Germany, Slovenia, Greece, Ireland, Estonia, and Spain have accepted the Indian Serum Institute-manufactured Covishield vaccine for travel. However, Covaxine is yet to be cleared by WHO.
Courtesy: The Times of India